366 related articles for article (PubMed ID: 21441454)
1. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
Hemon P; Jean-Louis F; Ramgolam K; Brignone C; Viguier M; Bachelez H; Triebel F; Charron D; Aoudjit F; Al-Daccak R; Michel L
J Immunol; 2011 May; 186(9):5173-83. PubMed ID: 21441454
[TBL] [Abstract][Full Text] [Related]
2. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE; Wolfers J; Martin-Garcia N; Gaulard P; Triebel F
Eur J Cancer; 2001 Sep; 37(13):1709-18. PubMed ID: 11527700
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
[TBL] [Abstract][Full Text] [Related]
4. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).
Andreae S; Buisson S; Triebel F
Blood; 2003 Sep; 102(6):2130-7. PubMed ID: 12775570
[TBL] [Abstract][Full Text] [Related]
5. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
Hannier S; Triebel F
Int Immunol; 1999 Nov; 11(11):1745-52. PubMed ID: 10545478
[TBL] [Abstract][Full Text] [Related]
6. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.
Camisaschi C; De Filippo A; Beretta V; Vergani B; Villa A; Vergani E; Santinami M; Cabras AD; Arienti F; Triebel F; Rodolfo M; Rivoltini L; Castelli C
J Invest Dermatol; 2014 Jul; 134(7):1893-1902. PubMed ID: 24441096
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.
Liang B; Workman C; Lee J; Chew C; Dale BM; Colonna L; Flores M; Li N; Schweighoffer E; Greenberg S; Tybulewicz V; Vignali D; Clynes R
J Immunol; 2008 May; 180(9):5916-26. PubMed ID: 18424711
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
9. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Oble DA; Loewe R; Yu P; Mihm MC
Cancer Immun; 2009 Apr; 9():3. PubMed ID: 19338264
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-melanoma interaction: role of surface molecules.
Becker JC; Bröcker EB
Recent Results Cancer Res; 1995; 139():205-14. PubMed ID: 7597291
[TBL] [Abstract][Full Text] [Related]
11. High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.
Buetow KH; Meador LR; Menon H; Lu YK; Brill J; Cui H; Roe DJ; DiCaudo DJ; Hastings KT
J Immunol; 2019 Nov; 203(10):2577-2587. PubMed ID: 31591149
[TBL] [Abstract][Full Text] [Related]
12. MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells.
Buisson S; Triebel F
Vaccine; 2003 Feb; 21(9-10):862-8. PubMed ID: 12547595
[TBL] [Abstract][Full Text] [Related]
13. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Huard B; Mastrangeli R; Prigent P; Bruniquel D; Donini S; El-Tayar N; Maigret B; Dréano M; Triebel F
Proc Natl Acad Sci U S A; 1997 May; 94(11):5744-9. PubMed ID: 9159144
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
[TBL] [Abstract][Full Text] [Related]
16. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.
Di Carlo E; Cappello P; Sorrentino C; D'Antuono T; Pellicciotta A; Giovarelli M; Forni G; Musiani P; Triebel F
J Pathol; 2005 Jan; 205(1):82-91. PubMed ID: 15586367
[TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
18. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A
Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
Jazirehi AR; Baritaki S; Koya RC; Bonavida B; Economou JS
Cancer Res; 2011 Feb; 71(4):1406-17. PubMed ID: 21159666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
